Drug intelligence / Profile preview

T-2000

Development stage: Unknown
Lead developer: Taro
Modality: Small Molecules

Overview

T-2000 is a small molecule drug that acts as a modulator of the GABA A receptor, exhibiting anticonvulsant activity with minimal sedation in animal models. It has been investigated for the treatment of myoclonus and essential tremor. T-2000 is an oxopyrimidine derivative and was patented by Taro Pharmaceutical Industries Ltd. as a tranquilizing agent.

Other names: 1,3-Dimethoxymethyl-5,5-diphenylbarbituric acid

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on T-2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-2000.